Henry J. Riordan, Ph.D., Executive Vice President of Medical and
Scientific Affairs and Global Lead for Neuroscience at Worldwide
Clinical Trials, shares his views on the relative insensitivity of
traditional cognitive outcome measures to describe the more subtle
and selective cognitive impairment associated with neurologic
disorders such as mild cognitive impairment/prodromal Alzheimer’s
disease, and psychiatric disorders such as depression, schizophrenia
and ADHD, as well as tracking treatment-related changes which has
resulted in a recent boon of cognitive composite measures.